(RxWiki News) The US Food and Drug Administration (FDA) has approved eye drops for patients undergoing cataract surgery.
The FDA recently approved BromSite (bromfenac) to prevent pain and treat inflammation in the eye for patients undergoing cataract surgery. BromSite is actually the first nonsteroidal anti-inflammatory drug (NSAID) approved specifically for patients undergoing cataract surgery.
NSAIDs work to decrease inflammation and pain because they stop the release of certain natural substances that cause pain and swelling.
In clinical trials, more patients who were given BromSite did not have pain the day after cataract surgery when compared to those patients who were given a placebo. Furthermore, more patients who were given BromSite did not have inflammation 15 days after cataract surgery when compared to those patients given a placebo.
Sun Ophthalmics' BromSite is expected to launch in the United States in the second half of 2016.
